CT/NG Testing Market By Product Type (Assays & Kits, Instruments , Analyzers); By Test Type (Laboratory Testing, Point-of-Care Testing); By Technology (Nucleic Acid Amplification Tests, Polymerase Chain Reaction, Immunodiagnostics); By End User (Diagnostic Labs, Hospitals & Clinics, Home Care Settings, Others); By Region – Growth, Share, Opportunities & Competitive Analysis, 2024 – 2032
CT/NG Testing Market size was valued at USD 1,051.87 million in 2018 to USD 1,874.06 million in 2024 and is anticipated to reach USD 3,690.64 million by 2032, at a CAGR of 8.23% during the forecast period.
REPORT ATTRIBUTE
DETAILS
Historical Period
2020-2024
Base Year
2024
Forecast Period
2025-2032
CT/NG Testing Market Size 2024
USD 1,874.06 Million
CT/NG Testing Market, CAGR
8.23%
CT/NG Testing Market Size 2032
USD 3,690.64 Million
The CT/NG Testing Market is led by prominent players such as Abbott Laboratories, Becton, Dickinson and Company, F. Hoffmann-La Roche Ltd., Hologic, Inc., Thermo Fisher Scientific, Qiagen N.V., Siemens AG, Bayer AG, and ZeptoMetrix LLC, all of which compete through advanced molecular diagnostic platforms, innovative assay kits, and strong distribution networks. These companies focus on expanding their portfolios with multiplex assays, automated analyzers, and point-of-care solutions to strengthen their global presence. North America emerged as the leading region in 2024, commanding 37% of the market share, driven by robust healthcare infrastructure, widespread adoption of nucleic acid amplification tests, and well-established screening programs.
Access crucial information at unmatched prices!
Request your sample report today & start making informed decisions powered by Credence Research Inc.!
The CT/NG Testing Market grew from USD 1,051.87 million in 2018 to USD 1,874.06 million in 2024 and will reach USD 3,690.64 million by 2032.
The assays & kits segment dominated with 68% share in 2024, driven by their convenience, rapid accuracy, and strong adoption across laboratory and point-of-care diagnostic settings.
The nucleic acid amplification tests (NAAT) segment led technology with 72% share in 2024, supported by unmatched sensitivity and specificity, with PCR further strengthening diagnostic accuracy.
North America commanded 37% share in 2024, driven by advanced infrastructure, government-led screening programs, and the presence of major diagnostic companies in the region.
Key players such as Abbott, Roche, Hologic, BD, Thermo Fisher, Qiagen, Siemens, Bayer, and ZeptoMetrix focus on molecular platforms, multiplex assays, and point-of-care solutions.
Market Segment Insights
By Product Type
The assays & kits segment accounted for 68% of the market share in 2024, making it the dominant product category. Its strong position is driven by the widespread adoption of ready-to-use kits for both laboratory and point-of-care testing. Increasing preference for accurate, rapid, and easy-to-use solutions further supports its growth, while instruments and analyzers contribute mainly through automation and advanced integration.
For instance, Mankind Pharma launched RAPID NEWS self-test kits in September 2024 for conditions such as dengue and urinary tract infections, empowering individuals in India to perform quick and private testing at home
By Test Type
The laboratory testing segment held 61% of the share in 2024, maintaining dominance due to its high sensitivity, established infrastructure, and broad patient access. Centralized labs continue to support large-scale screening programs, while hospitals and reference labs rely on validated platforms. However, point-of-care testing is expanding quickly with rising demand for rapid results in clinics and community health settings.
For example, Abbott’s ID NOW platform has enabled molecular COVID-19 testing with results in under 15 minutes and has been widely adopted in urgent care centers and pharmacies.
By Technology
The nucleic acid amplification tests (NAAT) segment captured 72% of the market in 2024, emerging as the clear leader. Its dominance is supported by superior sensitivity and specificity in detecting both Chlamydia trachomatis and Neisseria gonorrhoeae. Polymerase chain reaction (PCR), a core NAAT technology, further strengthens this segment, while immunodiagnostics hold a smaller share focused on low-cost, preliminary screening in resource-limited settings.
Key Growth Drivers
Rising Prevalence of STIs
The increasing incidence of Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) infections remains a major growth driver. Globally, these sexually transmitted infections are among the most commonly reported, creating strong demand for reliable diagnostics. Public health authorities emphasize large-scale screening and early detection, particularly among high-risk populations. This drives consistent adoption of molecular diagnostic technologies, ensuring sustained test volumes. Awareness campaigns and government initiatives further push testing uptake, cementing CT/NG testing as a vital public health priority worldwide.
For instance, Abbott’s Alinity m STI assay, launched in 2021, offers automated detection of CT and NG along with other pathogens, providing higher throughput for hospital and reference labs.
Advancements in Molecular Diagnostics
Technological innovation in molecular diagnostics strongly propels market expansion. Widespread adoption of nucleic acid amplification tests (NAAT) and polymerase chain reaction (PCR) platforms delivers unmatched sensitivity and specificity. These tools detect infections even in asymptomatic individuals, which represent a large portion of cases. Continuous product innovation, such as multiplex assays and automated workflows, enhances speed and reduces operator errors. The growing preference for molecular technologies in laboratories and point-of-care settings significantly boosts their role in infection surveillance and patient management.
For instance, the Abbott ID NOW platform, a widely used rapid NAAT system, delivers positive COVID-19 results in as little as five minutes and negative results in 13 minutes, making it a cornerstone for point-of-care testing.
Expansion of Point-of-Care Testing
The rapid growth of point-of-care (POC) testing drives accessibility and convenience in the CT/NG testing market. POC devices enable same-visit diagnosis and treatment, which is vital for improving patient compliance. Mobile clinics, urgent care centers, and community health programs increasingly use rapid kits to reduce diagnostic delays. Their ability to reach underserved and remote populations makes them essential in global control strategies. Combined with regulatory approvals and funding for decentralized testing, POC platforms provide strong momentum for market growth.
Key Trends & Opportunities
Integration of Multiplex Testing
Multiplex assays represent a rising trend, offering simultaneous detection of CT, NG, and other STIs in a single test. This reduces costs, saves time, and improves diagnostic efficiency. Healthcare systems adopting syndromic testing approaches prefer such tools for comprehensive infection panels. The opportunity lies in expanding multiplex offerings that integrate with automated platforms and point-of-care systems. This trend is likely to accelerate with growing demand for broad infection surveillance in public health initiatives.
For instance, Cepheid’s Xpert® CT/NG test, integrated into the GeneXpert platform, delivers dual detection within 90 minutes and is widely used in U.S. public health clinics.
Adoption of Digital Health and Remote Diagnostics
Digital health integration and telemedicine adoption are opening new opportunities in CT/NG testing. Home-based sample collection kits linked with telehealth platforms allow patients to access results without visiting clinics. This enhances privacy, convenience, and accessibility, especially for younger populations hesitant to seek in-person testing. The trend of digital-enabled care and remote monitoring positions CT/NG diagnostics to expand beyond traditional healthcare facilities, offering vendors opportunities to diversify product portfolios and build patient-centric testing solutions.
For instance, the Binx Health io CT/NG assay is a point-of-care clinical diagnostic test that delivers rapid results, supporting more efficient workflows for patient management, which can be complemented by telehealth services.
Key Challenges
Rising Antimicrobial Resistance
Antimicrobial resistance in Neisseria gonorrhoeae presents a critical challenge for disease management. Resistance reduces treatment efficacy, creating the need for constant surveillance and diagnostic updates. This complicates market dynamics, as diagnostics must evolve alongside emerging resistant strains. The pressure on manufacturers to integrate resistance detection capabilities in assays is increasing. Failure to address resistance risks undermining the long-term impact of current testing methods, posing both clinical and commercial hurdles for stakeholders in the CT/NG testing market.
Limited Access in Low-Resource Settings
Access to advanced CT/NG testing technologies remains limited in low-income and resource-constrained regions. High costs of molecular diagnostics, lack of trained personnel, and inadequate laboratory infrastructure hinder widespread adoption. Although point-of-care kits exist, their sensitivity is often lower compared to centralized lab systems. This disparity creates significant gaps in testing coverage and delays in treatment. Bridging affordability and accessibility challenges remains a pressing issue for governments and manufacturers seeking to expand market penetration globally.
Regulatory and Reimbursement Barriers
Complex regulatory pathways and inconsistent reimbursement policies restrain the CT/NG testing market. Obtaining approvals for new diagnostic assays often requires extensive clinical validation, delaying product launches. In several countries, reimbursement frameworks for STI testing are fragmented, limiting test affordability for patients. These factors discourage investment in innovative solutions and slow down adoption in both public and private healthcare systems. Streamlining regulatory approvals and creating uniform reimbursement models are essential to unlocking the market’s full growth potential.
Regional Analysis
North America
North America held the largest share of 37% in 2024, with revenues rising from USD 460.15 million in 2018 to USD 811.32 million in 2024. The region is projected to reach USD 1,602.19 million by 2032, growing at a CAGR of 8.3%. Strong healthcare infrastructure, favorable reimbursement policies, and high awareness of sexually transmitted infections (STIs) drive market leadership. The U.S. dominates due to extensive screening programs, adoption of nucleic acid amplification tests (NAAT), and strong presence of key diagnostic players. Expansion of point-of-care testing is further enhancing accessibility across urban and rural communities.
Europe
Europe accounted for 24% of the global share in 2024, with revenue increasing from USD 306.34 million in 2018 to USD 526.62 million in 2024. The market is forecasted to reach USD 978.05 million by 2032 at a CAGR of 7.4%. The region benefits from robust government-led STI surveillance programs and widespread use of molecular diagnostics. Germany, the UK, and France lead adoption due to advanced laboratory networks. Rising focus on multiplex testing and integration of digital health platforms enhances growth. However, uneven reimbursement policies across countries present challenges to uniform adoption.
Asia Pacific
Asia Pacific represented 17% of the market share in 2024, expanding rapidly from USD 193.23 million in 2018 to USD 374.50 million in 2024. It is projected to achieve USD 839.53 million by 2032, recording the highest CAGR of 10.0%. Rapid urbanization, rising STI prevalence, and government awareness programs drive demand. China, India, and Japan are key contributors due to large populations and increasing adoption of PCR-based assays. Growing acceptance of point-of-care diagnostics and telemedicine further supports expansion. Increasing healthcare investments and entry of global diagnostic firms make Asia Pacific the most dynamic growth region.
Latin America
Latin America captured 4% of the global share in 2024, with revenue rising from USD 47.58 million in 2018 to USD 83.67 million in 2024. The market is expected to reach USD 144.99 million by 2032, at a CAGR of 6.5%. Brazil and Mexico are the leading contributors, supported by expanding healthcare infrastructure and improved access to diagnostic kits. Rising public health initiatives targeting sexual health awareness also play a key role. However, inconsistent access to advanced molecular tests in rural areas limits widespread adoption. Partnerships with diagnostic companies are helping bridge these gaps.
Middle East
The Middle East accounted for 3% of the global market in 2024, growing from USD 29.58 million in 2018 to USD 48.19 million in 2024. It is projected to reach USD 80.14 million by 2032, reflecting a CAGR of 5.9%. GCC countries dominate due to better healthcare systems, while Turkey and Israel show rising adoption of PCR-based diagnostics. Increased government spending on infectious disease testing and screening campaigns supports demand. However, reliance on imported testing kits and limited regional manufacturing capacity remain significant barriers for long-term scalability.
Africa
Africa held the 2% market share in 2024, with revenues climbing from USD 15.00 million in 2018 to USD 29.75 million in 2024. The market is forecasted to reach USD 45.75 million by 2032, at a CAGR of 4.9%. The region faces challenges from limited laboratory infrastructure, high diagnostic costs, and lack of trained personnel. South Africa leads adoption due to relatively better healthcare infrastructure, followed by Egypt. Growing demand for affordable rapid point-of-care kits and international aid programs create opportunities. Yet, the gap between rural and urban access remains a persistent challenge.
Market Segmentations:
By Product Type
Assays & Kits
Instruments/Analyzers
By Test Type
Laboratory Testing
Point-of-Care Testing
By Technology
Nucleic Acid Amplification Tests (NAAT)
Polymerase Chain Reaction (PCR)
Immunodiagnostics
By End User
Diagnostic Labs
Hospitals & Clinics
Home Care Settings
Others
By Regions
North America:S., Canada, Mexico
Europe:UK, France, Germany, Italy, Spain, Russia, Rest of Europe
Asia Pacific:China, Japan, South Korea, India, Australia, Southeast Asia, Rest of Asia Pacific
Latin America:Brazil, Argentina, Rest of Latin America
Middle East:GCC Countries, Israel, Turkey, Rest of Middle East
Africa:South Africa, Egypt, Rest of Africa
Competitive Landscape
The CT/NG Testing Market is moderately consolidated, with leading companies controlling a significant share through advanced product portfolios and global distribution networks. Major players such as Abbott Laboratories, Becton, Dickinson and Company, F. Hoffmann-La Roche Ltd., Hologic, Inc., and Thermo Fisher Scientific, Inc. dominate by offering highly accurate molecular diagnostic platforms, including nucleic acid amplification tests (NAAT) and PCR-based assays. These firms continuously invest in research and development to launch multiplex kits, automated analyzers, and point-of-care solutions, strengthening their competitive edge. Companies like Qiagen N.V., Bayer AG, and Siemens AG expand their presence through strategic partnerships, acquisitions, and regional collaborations to tap into emerging markets. Smaller players, including ZeptoMetrix LLC, enhance competitiveness by supplying quality control products and supporting diagnostic labs. Intense competition focuses on innovation, regulatory approvals, and pricing strategies, with companies seeking to expand reach across high-growth regions such as Asia Pacific and Latin America.
In February 2023, Thermo Fisher Scientific Inc. acquired TIB Molbiol in Germany to expand its PCR-based diagnostic portfolio, strengthening CT/NG testing capabilities.
In December 2024, OraSure Technologies acquired Sherlock Biosciences, Inc. to develop rapid, potentially self-testing solutions for sexually transmitted infections including CT/NG.
In January 2025, Abbott gained FDA clearance for its simpli-COLLECT STI Test, a home-collection kit covering CT, NG, TV, and MG for lab processing.
In January 2025, Roche’s cobas liat CT/NG and CT/NG/MG assays received FDA clearance and a CLIA waiver, enabling rapid, point‑of‑care molecular testing with results in 20 minutes. These assays enhance diagnostic speed and accessibility in clinical and non‑lab environments
Report Coverage
The research report offers an in-depth analysis based on Product Type, Test Type, Technology, End User and Region. It details leading market players, providing an overview of their business, product offerings, investments, revenue streams, and key applications. Additionally, the report includes insights into the competitive environment, SWOT analysis, current market trends, as well as the primary drivers and constraints. Furthermore, it discusses various factors that have driven market expansion in recent years. The report also explores market dynamics, regulatory scenarios, and technological advancements that are shaping the industry. It assesses the impact of external factors and global economic changes on market growth. Lastly, it provides strategic recommendations for new entrants and established companies to navigate the complexities of the market.
Future Outlook
Demand for rapid and accurate diagnostic solutions will keep growing with rising global infection prevalence.
Point-of-care testing will increasingly expand across clinics, mobile healthcare units, and home-based diagnostic settings.
Multiplex assays enabling simultaneous detection of multiple STIs will gain significant preference in healthcare facilities.
Digital health platforms and home-based testing kits will improve accessibility, privacy, and patient diagnostic engagement.
Public health initiatives will continue driving large-scale screening programs focused on prevention and early detection.
Emerging economies will see rapid adoption supported by expanding healthcare infrastructure and increased testing investments.
Rising antimicrobial resistance in Neisseria gonorrhoeae will accelerate diagnostic innovation and resistance surveillance integration globally.
Laboratory automation and advanced analyzers will enhance diagnostic throughput, reduce costs, and improve turnaround efficiency.
Strategic partnerships between diagnostic companies and governments will expand testing access across underserved global populations.
Growing awareness campaigns will encourage voluntary STI testing, particularly among younger and high-risk population groups.
CHAPTER NO. 1: GENESIS OF THE MARKET
1.1 Market Prelude – Introduction & Scope
1.2 The Big Picture – Objectives & Vision
1.3 Strategic Edge – Unique Value Proposition
1.4 Stakeholder Compass – Key Beneficiaries CHAPTER NO. 2: EXECUTIVE LENS
2.1 Pulse of the Industry – Market Snapshot
2.2 Growth Arc – Revenue Projections (USD Million)
2.3. Premium Insights – Based on Primary Interviews CHAPTER NO. 3: CT/NG TESTING MARKET FORCES & INDUSTRY PULSE
3.1 Foundations of Change – Market Overview
3.2 Catalysts of Expansion – Key Market Drivers
3.2.1 Momentum Boosters – Growth Triggers
3.2.2 Innovation Fuel – Disruptive Technologies
3.3 Headwinds & Crosswinds – Market Restraints
3.3.1 Regulatory Tides – Compliance Challenges
3.3.2 Economic Frictions – Inflationary Pressures
3.4 Untapped Horizons – Growth Potential & Opportunities
3.5 Strategic Navigation – Industry Frameworks
3.5.1 Market Equilibrium – Porter’s Five Forces
3.5.2 Ecosystem Dynamics – Value Chain Analysis
3.5.3 Macro Forces – PESTEL Breakdown
3.6 Price Trend Analysis
3.6.1 Regional Price Trend
3.6.2 Price Trend by Product CHAPTER NO. 4: KEY INVESTMENT EPICENTER
4.1 Regional Goldmines – High-Growth Geographies
4.2 Product Frontiers – Lucrative Product Categories
4.3 Application Sweet Spots – Emerging Demand Segments CHAPTER NO. 5: REVENUE TRAJECTORY & WEALTH MAPPING
5.1 Momentum Metrics – Forecast & Growth Curves
5.2 Regional Revenue Footprint – Market Share Insights
5.3 Segmental Wealth Flow – Product Type & Technology Revenue CHAPTER NO. 6: TRADE & COMMERCE ANALYSIS
6.1. Import Analysis by Region
6.1.1. Global CT/NG Testing Market Import Revenue By Region
6.2. Export Analysis by Region
6.2.1. Global CT/NG Testing Market Export Revenue By Region CHAPTER NO. 7: COMPETITION ANALYSIS
7.1. Company Market Share Analysis
7.1.1. Global CT/NG Testing Market: Company Market Share
7.2. Global CT/NG Testing Market Company Revenue Market Share
7.3. Strategic Developments
7.3.1. Acquisitions & Mergers
7.3.2. New Product Launch
7.3.3. Regional Expansion
7.4. Competitive Dashboard
7.5. Company Assessment Metrics, 2024 CHAPTER NO. 8: CT/NG TESTING MARKET – BY PRODUCT TYPE SEGMENT ANALYSIS
8.1. CT/NG Testing Market Overview by Product Type Segment
8.1.1. CT/NG Testing Market Revenue Share By Product Type
8.2. Assays & Kits
8.3. Instruments/Analyzers CHAPTER NO. 9: CT/NG TESTING MARKET – BY TEST TYPE SEGMENT ANALYSIS
9.1. CT/NG Testing Market Overview by Test Type Segment
9.1.1. CT/NG Testing Market Revenue Share By Test Type
9.2. Laboratory Testing
9.3. Point-of-Care Testing CHAPTER NO. 10: CT/NG TESTING MARKET – BY TECHNOLOGY SEGMENT ANALYSIS
10.1. CT/NG Testing Market Overview by Technology Segment
10.1.1. CT/NG Testing Market Revenue Share By Technology
10.2. Nucleic Acid Amplification Tests (NAAT)
10.3. Polymerase Chain Reaction (PCR)
10.4. Immunodiagnostics CHAPTER NO. 11: CT/NG TESTING MARKET – BY END USER SEGMENT ANALYSIS
11.1. CT/NG Testing Market Overview by End User Segment
11.1.1. CT/NG Testing Market Revenue Share By End User
11.2. Diagnostic Labs
11.3. Hospitals & Clinics
11.4. Home Care Settings
11.5. Others CHAPTER NO. 12: CT/NG TESTING MARKET – REGIONAL ANALYSIS
12.1. CT/NG Testing Market Overview by Region Segment
12.1.1. Global CT/NG Testing Market Revenue Share By Region
12.1.2. Region
12.1.3. Global CT/NG Testing Market Revenue By Region
12.1.4. Product Type
12.1.5. Global CT/NG Testing Market Revenue By Product Type
12.1.6. Test Type
12.1.7. Global CT/NG Testing Market Revenue By Test Type
12.1.8. Technology
12.1.9. Global CT/NG Testing Market Revenue By Technology
12.1.10. End User
12.1.11. Global CT/NG Testing Market Revenue By End User CHAPTER NO. 13: NORTH AMERICA CT/NG TESTING MARKET – COUNTRY ANALYSIS
13.1. North America CT/NG Testing Market Overview by Country Segment
13.1.1. North America CT/NG Testing Market Revenue Share By Region
13.2. North America
13.2.1. North America CT/NG Testing Market Revenue By Country
13.2.2. Product Type
13.2.3. North America CT/NG Testing Market Revenue By Product Type
13.2.4. Test Type
13.2.5. North America CT/NG Testing Market Revenue By Test Type
13.2.6. Technology
13.2.7. North America CT/NG Testing Market Revenue By Technology
13.2.8. End User
13.2.9. North America CT/NG Testing Market Revenue By End User
13.3. U.S.
13.4. Canada
13.5. Mexico CHAPTER NO. 14: EUROPE CT/NG TESTING MARKET – COUNTRY ANALYSIS
14.1. Europe CT/NG Testing Market Overview by Country Segment
14.1.1. Europe CT/NG Testing Market Revenue Share By Region
14.2. Europe
14.2.1. Europe CT/NG Testing Market Revenue By Country
14.2.2. Product Type
14.2.3. Europe CT/NG Testing Market Revenue By Product Type
14.2.4. Test Type
14.2.5. Europe CT/NG Testing Market Revenue By Test Type
14.2.6. Technology
14.2.7. Europe CT/NG Testing Market Revenue By Technology
14.2.8. End User
14.2.9. Europe CT/NG Testing Market Revenue By End User
14.3. UK
14.4. France
14.5. Germany
14.6. Italy
14.7. Spain
14.8. Russia
14.9. Rest of Europe CHAPTER NO. 15: ASIA PACIFIC CT/NG TESTING MARKET – COUNTRY ANALYSIS
15.1. Asia Pacific CT/NG Testing Market Overview by Country Segment
15.1.1. Asia Pacific CT/NG Testing Market Revenue Share By Region
15.2. Asia Pacific
15.2.1. Asia Pacific CT/NG Testing Market Revenue By Country
15.2.2. Product Type
15.2.3. Asia Pacific CT/NG Testing Market Revenue By Product Type
15.2.4. Test Type
15.2.5. Asia Pacific CT/NG Testing Market Revenue By Test Type
15.2.6. Technology
15.2.7. Asia Pacific CT/NG Testing Market Revenue By Technology
15.2.8. End User
15.2.9. Asia Pacific CT/NG Testing Market Revenue By End User
15.3. China
15.4. Japan
15.5. South Korea
15.6. India
15.7. Australia
15.8. Southeast Asia
15.9. Rest of Asia Pacific CHAPTER NO. 16: LATIN AMERICA CT/NG TESTING MARKET – COUNTRY ANALYSIS
16.1. Latin America CT/NG Testing Market Overview by Country Segment
16.1.1. Latin America CT/NG Testing Market Revenue Share By Region
16.2. Latin America
16.2.1. Latin America CT/NG Testing Market Revenue By Country
16.2.2. Product Type
16.2.3. Latin America CT/NG Testing Market Revenue By Product Type
16.2.4. Test Type
16.2.5. Latin America CT/NG Testing Market Revenue By Test Type
16.2.6. Technology
16.2.7. Latin America CT/NG Testing Market Revenue By Technology
16.2.8. End User
16.2.9. Latin America CT/NG Testing Market Revenue By End User
16.3. Brazil
16.4. Argentina
16.5. Rest of Latin America CHAPTER NO. 17: MIDDLE EAST CT/NG TESTING MARKET – COUNTRY ANALYSIS
17.1. Middle East CT/NG Testing Market Overview by Country Segment
17.1.1. Middle East CT/NG Testing Market Revenue Share By Region
17.2. Middle East
17.2.1. Middle East CT/NG Testing Market Revenue By Country
17.2.2. Product Type
17.2.3. Middle East CT/NG Testing Market Revenue By Product Type
17.2.4. Test Type
17.2.5. Middle East CT/NG Testing Market Revenue By Test Type
17.2.6. Technology
17.2.7. Middle East CT/NG Testing Market Revenue By Technology
17.2.8. End User
17.2.9. Middle East CT/NG Testing Market Revenue By End User
17.3. GCC Countries
17.4. Israel
17.5. Turkey
17.6. Rest of Middle East CHAPTER NO. 18: AFRICA CT/NG TESTING MARKET – COUNTRY ANALYSIS
18.1. Africa CT/NG Testing Market Overview by Country Segment
18.1.1. Africa CT/NG Testing Market Revenue Share By Region
18.2. Africa
18.2.1. Africa CT/NG Testing Market Revenue By Country
18.2.2. Product Type
18.2.3. Africa CT/NG Testing Market Revenue By Product Type
18.2.4. Test Type
18.2.5. Africa CT/NG Testing Market Revenue By Test Type
18.2.6. Technology
18.2.7. Africa CT/NG Testing Market Revenue By Technology
18.2.8. End User
18.2.9. Africa CT/NG Testing Market Revenue By End User
18.3. South Africa
18.4. Egypt
18.5. Rest of Africa CHAPTER NO. 19: COMPANY PROFILES
19.1. Abbott Laboratories
19.1.1. Company Overview
19.1.2. Product Portfolio
19.1.3. Financial Overview
19.1.4. Recent Developments
19.1.5. Growth Strategy
19.1.6. SWOT Analysis
19.2. Becton, Dickinson and Company
19.3. ZeptoMetrix LLC (Antylia Scientific)
19.4. Danaher Corporation
19.5. F. Hoffmann-La Roche Ltd.
19.6. Hologic, Inc.
19.7. Thermo Fisher Scientific, Inc.
19.8. Bayer AG
19.9. Qiagen N.V.
19.10. Siemens AG
Request Sample
We prioritize the confidentiality and security of your data. Our promise: your information remains private.
Ready to Transform Data into Decisions?
Request Your Sample Report and Start Your Journey of Informed Choices
Providing the strategic compass for industry titans.
Frequently Asked Questions:
What is the current market size for CT/NG Testing Market, and what is its projected size in 2032?
The CT/NG Testing Market was USD 1,051.87 million in 2018, reached USD 1,874.06 million in 2024, and is expected to achieve USD 3,690.64 million by 2032.
At what Compound Annual Growth Rate is the CT/NG Testing Market projected to grow between 2025 and 2032?
The CT/NG Testing Market is projected to expand steadily at a CAGR of 8.23% between 2025 and 2032, driven by technological advancements and rising global testing demand.
Which CT/NG Testing Market segment held the largest share in 2024?
The assays & kits segment held the largest share of nearly 68% in 2024, driven by their convenience, rapid diagnostic accuracy, and widespread adoption across clinical settings.
What are the primary factors fueling the growth of the CT/NG Testing Market?
Key growth drivers include rising STI prevalence worldwide, significant advancements in molecular diagnostic technologies, and expanding adoption of decentralized point-of-care testing platforms across both developed and emerging markets.
Who are the leading companies in the CT/NG Testing Market?
Leading companies include Abbott Laboratories, Becton, Dickinson and Company, F. Hoffmann-La Roche Ltd., Hologic, Thermo Fisher Scientific, Qiagen N.V., Siemens AG, Bayer AG, and ZeptoMetrix LLC.
Which region commanded the largest share of the CT/NG Testing Market in 2024?
North America commanded the largest share of 37% in 2024, supported by robust healthcare infrastructure, strong government-led screening programs, and significant adoption of advanced molecular diagnostics.
About Author
Shweta Bisht
Healthcare & Biotech Analyst
Shweta is a healthcare and biotech researcher with strong analytical skills in chemical and agri domains.
The Medical Device Packaging Market was valued at USD 38.2 billion in 2024 and is projected to reach USD 61.3 billion by 2032, expanding at a CAGR of 6.1% during the forecast period.
The Global DC Power Supply Module Market size was valued at USD 1,306.43 million in 2018 to USD 1,850.78 million in 2024 and is anticipated to reach USD 2,968.92 million by 2032, at a CAGR of 5.67% during the forecast period
The Global Data Privacy Software Market size was valued at USD 613.65 million in 2018 to USD 2,801.65 million in 2024 and is anticipated to reach USD 21,219.81 million by 2032, at a CAGR of 28.80% during the forecast period.
The Global Data Catalog Market size was valued at USD 636.21 million in 2018 to USD 1,375.49 million in 2024 and is anticipated to reach USD 3,854.60 million by 2032, at a CAGR of 12.81% during the forecast period.</p
The Global Custom Inserts Market size was valued at USD 485.12 million in 2018 to USD 868.65 million in 2024 and is anticipated to reach USD 2,005.35 million by 2032, at a CAGR of 10.27% during the forecast period.
Offshore Pipeline Infrastructure Market size was valued at USD 45.6 billion in 2024 and is anticipated to reach USD 63.9 billion by 2032, at a CAGR of 4.3% during the forecast period.
Meat Starter Cultures Market size was valued at USD 73.9 million in 2024 and is anticipated to reach USD 104.3 million by 2032, at a CAGR of 4.4% during the forecast period.
The Non-Alcoholic Wine and Beer Market size was valued at USD 43.3 billion in 2024 and is projected to reach USD 94.9 billion by 2032, growing at a CAGR of 10.3% during the forecast period.
Noise Mitigation System Market size was valued at USD 45.1 billion in 2024 and is anticipated to reach USD 63.1 billion by 2032, at a CAGR of 4.3% during the forecast period.
Purchase Options
The report comes as a view-only PDF document, optimized for individual clients. This version is recommended for personal digital use and does not allow printing. Use restricted to one purchaser only.
$4999
To meet the needs of modern corporate teams, our report comes in two formats: a printable PDF and a data-rich Excel sheet. This package is optimized for internal analysis. Unlimited users allowed within one corporate location (e.g., regional office).
$6999
The report will be delivered in printable PDF format along with the report’s data Excel sheet. This license offers 100 Free Analyst hours where the client can utilize Credence Research Inc. research team. Permitted for unlimited global use by all users within the purchasing corporation, such as all employees of a single company.
Thank you for the data! The numbers are exactly what we asked for and what we need to build our business case.
Materials Scientist (privacy requested)
The report was an excellent overview of the Industrial Burners market. This report does a great job of breaking everything down into manageable chunks.
